Kiora Pharmaceuticals (KPRX) Competitors $2.73 +0.11 (+4.20%) Closing price 04:00 PM EasternExtended Trading$2.68 -0.05 (-1.79%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. ITRM, OKUR, MRSN, XLO, KLTO, ESLA, RNXT, SCYX, CLSD, and AKTXShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Iterum Therapeutics (ITRM), OnKure Therapeutics (OKUR), Mersana Therapeutics (MRSN), Xilio Therapeutics (XLO), Klotho Neurosciences (KLTO), Estrella Immunopharma (ESLA), RenovoRx (RNXT), SCYNEXIS (SCYX), Clearside Biomedical (CLSD), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors Iterum Therapeutics OnKure Therapeutics Mersana Therapeutics Xilio Therapeutics Klotho Neurosciences Estrella Immunopharma RenovoRx SCYNEXIS Clearside Biomedical Akari Therapeutics Kiora Pharmaceuticals (NASDAQ:KPRX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings. Do institutionals and insiders believe in KPRX or ITRM? 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is KPRX or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -47.17% -34.00% Iterum Therapeutics N/A N/A -65.01% Do analysts prefer KPRX or ITRM? Kiora Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 266.30%. Iterum Therapeutics has a consensus target price of $9.00, indicating a potential upside of 1,109.68%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, KPRX or ITRM? Kiora Pharmaceuticals has a beta of -0.64, meaning that its share price is 164% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Which has higher earnings and valuation, KPRX or ITRM? Kiora Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.58$3.60M-$2.91-0.94Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.88 Does the media refer more to KPRX or ITRM? In the previous week, Iterum Therapeutics had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Iterum Therapeutics and 0 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score. Company Overall Sentiment Kiora Pharmaceuticals Neutral Iterum Therapeutics Neutral SummaryIterum Therapeutics beats Kiora Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.36M$2.80B$5.82B$9.74BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-0.9422.6131.1525.97Price / Sales0.58751.86475.57123.18Price / Cash2.14173.2237.1558.38Price / Book0.425.869.116.39Net Income$3.60M$31.83M$3.26B$265.66M7 Day Performance-6.83%1.80%2.11%1.98%1 Month Performance-9.90%4.36%5.12%1.33%1 Year Performance-26.22%11.44%31.25%21.15% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.3789 of 5 stars$2.73+4.2%$10.00+266.3%-36.1%$9.36M$16.02M-0.9410Gap UpITRMIterum Therapeutics1.9099 of 5 stars$0.82-6.2%$9.00+1,002.9%-42.3%$36.62MN/A-0.9610OKUROnKure Therapeutics3.2339 of 5 stars$2.66-4.9%$32.33+1,114.2%N/A$36.34MN/A-0.56N/AMRSNMersana Therapeutics4.237 of 5 stars$7.28-1.4%$56.60+677.5%-76.7%$36.33M$34.77M-0.50150XLOXilio Therapeutics2.7843 of 5 stars$0.70-1.3%$3.00+329.8%-24.7%$36.18M$6.34M-0.9270KLTOKlotho NeurosciencesN/A$0.77-2.1%N/AN/A$35.46MN/A-2.14N/AEarnings ReportGap UpESLAEstrella Immunopharma2.8877 of 5 stars$0.94+2.7%$16.00+1,611.2%-37.6%$34.66MN/A-3.60N/ARNXTRenovoRx2.9115 of 5 stars$0.94+0.1%$7.25+670.5%-15.7%$34.41M$40K-2.486News CoverageShort Interest ↓Analyst RevisionSCYXSCYNEXIS1.0345 of 5 stars$0.80-0.2%N/A-54.3%$33.58M$3.75M-2.0060News CoverageAnalyst RevisionCLSDClearside Biomedical2.2672 of 5 stars$0.41-3.7%$4.20+924.4%-60.1%$32.19M$4.17M-1.1130Negative NewsAKTXAkari Therapeutics2.3884 of 5 stars$1.00flat$5.00+400.0%-74.2%$32.18MN/A0.009 Related Companies and Tools Related Companies Iterum Therapeutics Competitors OnKure Therapeutics Competitors Mersana Therapeutics Competitors Xilio Therapeutics Competitors Klotho Neurosciences Competitors Estrella Immunopharma Competitors RenovoRx Competitors SCYNEXIS Competitors Clearside Biomedical Competitors Akari Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access